Acute Pain: Overview of Management
NUCYNTA®, a molecule with mu-opioid agonist activity and norepinephrine
reuptake inhibition, has been approved for the relief of moderate to
severe acute pain in patients 18 years of age or older. NUCYNTA® has
been clinically tested in multiple pain models and found to combine
opioid efficacy with favorable gastrointestinal tolerability.
Click here for pdf.
Acute Pain: Overview of Management
NUCYNTA®, a molecule with mu-opioid agonist activity and norepinephrine reuptake inhibition, has been approved for the relief of moderate to severe acute pain in patients 18 years of age or older. NUCYNTA® has been clinically tested in multiple pain models and found to combine opioid efficacy with favorable gastrointestinal tolerability.
Click here for pdf.
Continuing Education
$7.95 Per CE Exam or $69 for 12 Lessons
-
• April 2026 • 2.00 Credits
Managing HIV Coinfections and Complications
-
Pain Management • March 2026 • 2.00 Credits
Updated Guidance for Opioid Use in Pain Management
-
Cardiovascular • February 2026 • 2.00 Credits
Managing Modifiable Risk Factors in Chronic Coronary Disease
Copyright © 2000 - 2024 Jobson Medical Information LLC unless otherwise noted. All rights reserved. Reproduction in whole or in part without permission is prohibited.